AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27841040 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve for fecal lactoferrin
Number of subjects: 68
Study 27842560 — intervention group
Group type: EXPERIMENTAL
Intervention: AposTherapy (biomechanical treatment)
Number of subjects: 17
Study 27843120 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone
Number of subjects: 57
Study 27843136 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) as part of high-dose methotrexate-based immuno-chemotherapy
Number of subjects: 0
Study 27843549 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush
Number of subjects: 21
Study 27843549 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam swab
Number of subjects: 21
Study 27843557 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-included diet (56 g, 366 kcal per day)
Number of subjects: 112
Study 27843557 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-included diet with calorie regulation
Number of subjects: 112
Study 27843564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day maintenance dose (MD)
Number of subjects: 193
Study 27843564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg/day maintenance dose (MD)
Number of subjects: 193
Study 27843586 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 alone
Number of subjects: 658
Study 27843586 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil alone
Number of subjects: 658
Study 27843586 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 658
Study 27843586 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 658
Study 27843597 — intervention group
Group type: EXPERIMENTAL
Intervention: panitumumab+FOLFOX4
Number of subjects: 0
Study 27843597 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 0
Study 27843623 — intervention group
Group type: EXPERIMENTAL
Intervention: tivantinib (ARQ 197) plus erlotinib
Number of subjects: 45
Study 27843625 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (recPRAME) with AS15, 20 µg in cohort 1
Number of subjects: 66
Study 27843625 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (recPRAME) with AS15, 100 µg in cohort 2
Number of subjects: 66
Study 27843625 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (recPRAME) with AS15, 500 µg in cohort 3
Number of subjects: 66
Study 27843743 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT)
Number of subjects: 0
Study 27843743 — intervention group
Group type: COMPARATOR
Intervention: Functional gait training (PT)
Number of subjects: 0
Study 27844326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functions (working memory, inhibition, attention, task-switching)
Number of subjects: 0
Study 27844326 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory strategy use
Number of subjects: 0
Study 27845298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus sofosbuvir (SOF) with ribavirin (RBV), n=16
Number of subjects: 55
Study 27845298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus sofosbuvir (SOF) without ribavirin (RBV), n=39
Number of subjects: 55
Study 27845298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus sofosbuvir (SOF) (with or without RBV)
Number of subjects: 55
Study 27845298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus sofosbuvir (SOF)
Number of subjects: 55
Study 27845998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold Absorb
Number of subjects: 30
Study 27845998 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 30
Study 27846057 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of disseminated fusariosis in children
Number of subjects: 10
Study 27846060 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated chimeric Japanese encephalitis vaccine booster dose
Number of subjects: 50
Study 27846134 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 200
Study 27846134 — intervention group
Group type: COMPARATOR
Intervention: Controls (nonsmokers)
Number of subjects: 200
Study 27846610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies
Number of subjects: 240
Study 27846807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct TF-TAVI (without pre-dilation)
Number of subjects: 0
Study 27846807 — intervention group
Group type: COMPARATOR
Intervention: Standard TF-TAVI (with pre-dilation)
Number of subjects: 0
Study 27846821 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 or 1600 IU vitamin D3 with calcium (one or two tablets daily) for 10 months
Number of subjects: 71
Study 27846908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute inflammatory abdominal disease (n=10)
Number of subjects: 30
Study 27846908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing elective pancreatic resection (n=10)
Number of subjects: 30
Study 27846913 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with cisplatin, 5-fluorouracil, and docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 0
Study 27846913 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 0
Study 27847279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and velpatasvir with ribavirin for 12 weeks (n=87)
Number of subjects: 1701
Study 27847279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir with ribavirin for 12 or 24 weeks (n=401)
Number of subjects: 1701
Study 27847279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin-free sofosbuvir and velpatasvir for 12 or 24 weeks (n=1213)
Number of subjects: 1701
Study 27847279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and velpatasvir (regimens with ribavirin)
Number of subjects: 1701
Study 27847352 — intervention group
Group type: EXPERIMENTAL
Intervention: BroHealth only
Number of subjects: 1200
Study 27847352 — intervention group
Group type: EXPERIMENTAL
Intervention: BroHealth and telephone-based job coaching service
Number of subjects: 1200
Study 27847352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1200
Study 27847367 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB-4C vaccine
Number of subjects: 20
Study 27847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reasoning training (8 hours total, 2 hours/week in small groups)
Number of subjects: 27
Study 27847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reasoning training
Number of subjects: 27
Study 27847545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone Gel, 7.5%
Number of subjects: 0
Study 27847545 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27847634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 0
Study 27847634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks (2q8)
Number of subjects: 0
Study 27848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapies in patients with significant valvular disease (SVD)
Number of subjects: 5987
Study 27848065 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC) therapies in patients with non-significant valvular disease (NSVD)
Number of subjects: 5987
Study 27848182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab (10 mg/kg, increased to 20 mg/kg if no DLTs), lenalidomide (25 mg orally), dexamethasone (28 mg orally plus 8 mg intravenously on elotuzumab days; 40 mg orally on non-elotuzumab days)
Number of subjects: 6
Study 27849125 — intervention group
Group type: EXPERIMENTAL
Intervention: OT329 SOLIS 100/50
Number of subjects: 879
Study 27849125 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAIR DISKUS 100/50
Number of subjects: 879
Study 27849125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 879
Study 27849340 — intervention group
Group type: EXPERIMENTAL
Intervention: SSIA Cetuximab
Number of subjects: 1
Study 27851688 — intervention group
Group type: EXPERIMENTAL
Intervention: Brincidofovir (BCV)
Number of subjects: 3
Study 27851688 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Cidofovir (CDV)
Number of subjects: 3
Study 27852119 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg plus a single OAD (sulfonylurea)
Number of subjects: 374
Study 27852119 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg plus a single OAD (glinide)
Number of subjects: 374
Study 27852119 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg plus a single OAD (other OADs)
Number of subjects: 374
Study 27852119 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (uptitrated to 50 mg after Week 4)
Number of subjects: 374
Study 27852260 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids for 2 weeks and budesonide/formoterol for 12 weeks
Number of subjects: 51
Study 27852260 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids for 2 weeks
Number of subjects: 51
Study 27852260 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol for 12 weeks
Number of subjects: 51
Study 27852615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary n-6:n-3 ratio
Number of subjects: 78
Study 27852615 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma n-6:n-3 ratio
Number of subjects: 78
Study 27852615 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between dietary n-6:n-3 ratio and n-3
Number of subjects: 78
Study 27852615 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between plasma n-6:n-3 ratio and n-3
Number of subjects: 78
Study 27852618 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk consumption
Number of subjects: 2745
Study 27852618 — intervention group
Group type: COMPARATOR
Intervention: 1% milk consumption
Number of subjects: 2745
Study 27852653 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial septal shunt device implantation
Number of subjects: 64
Study 27852713 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) levels of 5, 10, and 15 cm H2O
Number of subjects: 0
Study 27852955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx (oral trimethoprim-sulfamethoxazole or minocycline plus oral rifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days; environmental decontamination for 21 days)
Number of subjects: 45
Study 27852955 — intervention group
Group type: COMPARATOR
Intervention: Obs (observation)
Number of subjects: 45
Study 27852955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx
Number of subjects: 45
Study 27852955 — intervention group
Group type: COMPARATOR
Intervention: Obs
Number of subjects: 45
Study 27853379 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (with pemetrexed or gemcitabine)
Number of subjects: 68
Study 27853737 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle based confocal laser endomicroscopy
Number of subjects: 0
Study 27853737 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27853981 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 40
Study 27853981 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus regimen (switching to basal-bolus)
Number of subjects: 40
Study 27855070 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 27855070 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0
Study 27855070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 0
Study 27855070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 0
Study 27855112 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (standard dose)
Number of subjects: 0
Study 27855386 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 1
Study 27855386 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/etoposide (rechallenge)
Number of subjects: 1
Study 27855483 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for 32 weeks
Number of subjects: 180
Study 27855483 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for 16 weeks followed by placebo for 16 weeks
Number of subjects: 180
Study 27855483 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 32 weeks
Number of subjects: 180
Study 27855624 — intervention group
Group type: COMPARATOR
Intervention: Long-term PDE5 inhibition (PDE5 inhibitors)
Number of subjects: 0
Study 27855624 — intervention group
Group type: COMPARATOR
Intervention: Estrogen receptor modulation with PDE5 inhibitors
Number of subjects: 0
Study 27855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorder diagnosis in men
Number of subjects: 384
Study 27855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorder diagnosis in women
Number of subjects: 384
Study 27855664 — intervention group
Group type: COMPARATOR
Intervention: Toxicology screening results
Number of subjects: 384
Study 27855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level in men
Number of subjects: 384
Study 27855684 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectancies of return to work
Number of subjects: 574
Study 27855684 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of job satisfaction
Number of subjects: 574
Study 27855684 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in predictors
Number of subjects: 574
Study 27855998 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.0125 mg/kg/d
Number of subjects: 42
Study 27855998 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.025 mg/kg/d
Number of subjects: 42
Study 27855998 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Number of subjects: 42
Study 27855998 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 42
Study 27855999 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwood Procedure
Number of subjects: 0
Study 27856405 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth technology (computer tablet)
Number of subjects: 32
Study 27856405 — intervention group
Group type: COMPARATOR
Intervention: Home visitor-administered, paper-based method
Number of subjects: 32
Study 27856475 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR (Thoracic Endovascular Aortic Repair)
Number of subjects: 24
Study 27856475 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (Control)
Number of subjects: 24
Study 27856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (ON)
Number of subjects: 120
Study 27856480 — intervention group
Group type: EXPERIMENTAL
Intervention: No pharmacological treatment (OFF)
Number of subjects: 120
Study 27856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech tasks (acoustic and perceptual measures)
Number of subjects: 120
Study 27856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures
Number of subjects: 120
Study 27856480 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched volunteers (Control)
Number of subjects: 120
Study 27856951 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Lp(a) levels (>30 mg/dL)
Number of subjects: 250
Study 27856951 — intervention group
Group type: COMPARATOR
Intervention: Normal Lp(a) levels (≤30 mg/dL)
Number of subjects: 250
Study 27857630 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) in addition to conventional physical therapy
Number of subjects: 24
Study 27857630 — intervention group
Group type: COMPARATOR
Intervention: Written information in addition to conventional physical therapy
Number of subjects: 24
Study 27857759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow derived stem cells (BMSC)
Number of subjects: 1
Study 27858851 — intervention group
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Number of subjects: 52
Study 27858851 — intervention group
Group type: COMPARATOR
Intervention: sETT
Number of subjects: 52
Study 27859303 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) with postoperative medical management
Number of subjects: 363
Study 27859303 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 363
Study 27859303 — intervention group
Group type: COMPARATOR
Intervention: Prior ESS
Number of subjects: 363
Study 27859303 — intervention group
Group type: COMPARATOR
Intervention: Worse preoperative polyposis severity
Number of subjects: 363
Study 27860160 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 1 week
Number of subjects: 12
Study 27860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental and peer pressure to be thin
Number of subjects: 196
Study 27861509 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-Chloroquine (AZCQ) 250/155 mg, single 3-day course
Number of subjects: 168
Study 27861524 — intervention group
Group type: EXPERIMENTAL
Intervention: High S. aureus density in throat specimens
Number of subjects: 195
Study 27861524 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbations
Number of subjects: 195
Study 27861524 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus small-colony variants (SCVs)
Number of subjects: 195
Study 27861524 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection with Stenotrophomonas maltophilia
Number of subjects: 195
Study 27861524 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 195
Study 27861833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitals with strong approaches to follow-up
Number of subjects: 9
Study 27861833 — intervention group
Group type: COMPARATOR
Intervention: High underuse sites
Number of subjects: 9
Study 27862043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 903
Study 27862700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide (15 ng/kg/min)
Number of subjects: 0
Study 27862700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27862721 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV + TDF
Number of subjects: 34
Study 27862721 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM + TDF
Number of subjects: 34
Study 27862767 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 27863097 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcoholic fatty liver disease (NAFLD) patients
Number of subjects: 105
Study 27863153 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk total adiponectin
Number of subjects: 147
Study 27863153 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk leptin
Number of subjects: 147
Study 27863153 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk adipokines
Number of subjects: 147
Study 27863192 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy
Number of subjects: 123
Study 27863194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 5 mg once per day for 21 days per 28-day cycle
Number of subjects: 22
Study 27863197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks
Number of subjects: 655
Study 27863197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study 27863201 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice per day
Number of subjects: 136
Study 27863522 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed antipsychotic medication regimens (including types, combinations, and Daily Defined Dose equivalent)
Number of subjects: 82
Study 27863522 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy and higher doses of antipsychotics
Number of subjects: 82
Study 27863522 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine CVD risk screening
Number of subjects: 82
Study 27864013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 617
Study 27864641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodized tapered implants with a conical connection and integrated platform shifting
Number of subjects: 97
Study 27865255 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based guideline recommendations for symptom management in women with VC or VIN
Number of subjects: 14
Study 27865372 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab and paclitaxel
Number of subjects: 40
Study 27865764 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV.sFLT-1 gene therapy
Number of subjects: 32
Study 27865764 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab injections (control)
Number of subjects: 32
Study 27865979 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine transplant
Number of subjects: 0
Study 27866244 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m²
Number of subjects: 41
Study 27866303 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia (RA)
Number of subjects: 0
Study 27866303 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthetics and opioids
Number of subjects: 0
Study 27866303 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 27866310 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry measurements (Forced Inspiratory Vital Capacity)
Number of subjects: 202
Study 27866310 — intervention group
Group type: COMPARATOR
Intervention: Conventional airway assessment techniques
Number of subjects: 202
Study 27866695 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable aripiprazole
Number of subjects: 986
Study 27866695 — intervention group
Group type: COMPARATOR
Intervention: Oral formulations of antipsychotics (including risperidone, olanzapine, aripiprazole, zuclopenthixol, fluphenazine, and haloperidol)
Number of subjects: 986